Brainomix, a UK-based medical technology company, has received clearance from the US Food and Drug Administration (FDA) for its flagship stroke AI imaging software.
The software, called e-ASPECTS, uses artificial intelligence to rapidly and accurately assess brain scans for signs of stroke, helping clinicians make better-informed treatment decisions.
In a recent article by Health Tech Digital they discuss the significance of the FDA clearance for Brainomix and how the e-ASPECTS software can improve stroke diagnosis and patient outcomes.
Check out the full article here: healthtechdigital.com
Posted by:
Cure Talent